Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection
Cynthia Portal‐Celhay(New York University), Amber Mottola, Nayna Paryani, Andrea T. Hooper(Regeneron (United States)), Cynthia X. Pan(Anna Needs Neuroblastoma Answers), Dina Gibson, Ned Braunstein(Anna Needs Neuroblastoma Answers), Kristy Carroll, Yuhwen Soo(Regeneron (United States)), Thomas Norton(Anna Needs Neuroblastoma Answers), Anita Kohli(Anna Needs Neuroblastoma Answers), Jennifer D. Hamilton(Regeneron (United States)), Dickson Ellington, Leah Lipsich(Anna Needs Neuroblastoma Answers), Jessica Laabs, Ashley Carney, Zachary Sheppard, Dario Altamirano, Munib Daudjee, Bret J. Musser(Regeneron (United States)), Amanda McFarland, Alina Baum(Regeneron (United States)), Bari Kowal(Anna Needs Neuroblastoma Answers), Gregory P. Geba(Regeneron (United States)), Christos A. Kyratsous(Regeneron (United States)), Roxana Stoici, Janie Parrino, Eduardo Forleo‐Neto(Regeneron (United States)), Vicki McIntyre, Najmuddin Karimjee, Natalee Calais, Kenneth Kim, Will Eagan(Regeneron (United States)), Neil Stahl(Arthritis and Rheumatism Associates), Gary Herman(Regeneron (United States)), George D. Yancopoulos(Regeneron (United States)), Yessica Sachdeva(Anna Needs Neuroblastoma Answers), Adil Fatakia, Wendy Kampman(Anna Needs Neuroblastoma Answers), Victorine Ekoko, Karen Marler, Yun‐Ji Kim(Anna Needs Neuroblastoma Answers), Jason Ahn, David M. Weinreich(Regeneron (United States)), K. C. Turner(Regeneron (United States)), A. Thomas DiCioccio(Anna Needs Neuroblastoma Answers), John D. Davis(Providence College), Adnan Mahmood(Anna Needs Neuroblastoma Answers), Lilia Roque-Guerrero
Cited by 17
Related Papers
Vascular-specific growth factors and blood vessel formation
|Nature|2000|3.7k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
|New England Journal of Medicine|2020|1.8k
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
|New England Journal of Medicine|2021|1.7k